Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases. www.wired.com/story/crispr...

Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The @fda.gov outlines a path to market entry for products where a randomized trial is not feasible. Learn more: nej.md/4nUQdcl

My first-author paper was published today in Nature Biomedical Engineering! Here we describe how incorporating DNA substitutions into various positions of the Cas9 guide RNA protospacer can enhance the precision and performance of adenine base editors. 🧬 ✂️

🧬Proud to share "Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs" my 1st first-author paper of my PhD, co-first-authored with the brilliant Dr. @mnwhittaker.bsky.social, is out today in Nature Biomedical Engineering! www.nature.com/articles/s41...

Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable go.nature.com/4kCD1Y3